Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many bleeding/interaction-related claims are partially aligned with label text about increased bleeding risk and concomitant antithrombotic medications, but numerous specific interaction assertions (e.g., NSAID/aspirin dosing thresholds, OTC product safety, vitamin/antacid/antihistamine interactions, acetaminophen safety, surgery/bleeding-disorder OTC cautions) are not supported by the supplied prescribing information and some are potentially overconfident.
Category Scores
Accurate Statements
VASCEPA is associated with an increased risk of bleeding.
Label 5.3 Bleeding: “VASCEPA is associated with an increased risk of bleeding.”
The incidence of bleeding is greater in patients receiving concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin.
Label 5.3 Bleeding: “The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.”
Monitor patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents for bleeding.
Label 7.1: “Monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding.”
Inform patients VASCEPA may increase bleeding risk, especially with other antithrombotic agents.
Label 17: “Inform patients that VASCEPA may increase their risk for bleeding, especially if they are receiving other antithrombotic agents [see Warnings and Precautions (5.3)].”
Unsupported Statements
Vascepa increases bleeding risk when combined with antiplatelet drugs like aspirin.
The label supports increased bleeding incidence with concomitant antithrombotic medications and gives aspirin as an example, but the user’s statement is framed as a specific drug-class interaction without the label’s wording of incidence being greater; still partially supported—however the provided label excerpt supports aspirin in that context. Marking as unsupported because the statement is overly specific relative to supplied excerpts about NSAIDs and class effects.
Vascepa increases bleeding risk when combined with NSAIDs such as ibuprofen/naproxen.
The supplied prescribing information excerpt discusses antithrombotic medications (e.g., aspirin, clopidogrel, warfarin) and concomitant anticoagulants/antiplatelet agents, but does not mention NSAIDs or ibuprofen/naproxen in the provided sections.
Vascepa effects on platelet aggregation and blood thinning contribute to increased bleeding risk with antiplatelet drugs and NSAIDs.
The provided label excerpts do not describe platelet aggregation/blood thinning mechanisms or mention NSAIDs; only bleeding risk and monitoring are provided.
In the REDUCE-IT trial, higher bleeding events were noted with aspirin use.
The label excerpt provides overall bleeding incidence and notes concomitant antithrombotic medications such as aspirin, but does not provide a statement that the REDUCE-IT trial specifically showed higher bleeding events with aspirin use versus no aspirin use.
In the REDUCE-IT trial, most bleeding events associated with aspirin were mild (e.g., bruising, epistaxis).
The provided label excerpts include bleeding incidence totals and seriousness counts, but do not provide severity breakdowns (bruising, epistaxis) associated with aspirin.
Avoid high-dose aspirin (>325 mg/day) without medical advice when taking Vascepa.
No aspirin dosage threshold is provided in the supplied label excerpts.
Avoid chronic NSAID use without medical advice when taking Vascepa.
No NSAID-specific caution is included in the supplied label excerpts.
Low-dose aspirin (81 mg) for heart protection is often tolerated but requires monitoring when taking Vascepa.
No low-dose aspirin (81 mg) statement regarding tolerance is provided in the supplied label excerpts; only monitoring is recommended for concomitant anticoagulants/antiplatelet agents.
Acetaminophen has no known significant interactions with Vascepa.
No acetaminophen interaction information is provided in the supplied label excerpts.
Acetaminophen is a safer OTC pain reliever option for those on Vascepa because it lacks antiplatelet effects of NSAIDs.
The supplied label excerpts do not address comparative OTC pain reliever safety or acetaminophen mechanisms.
Liver function should be watched if acetaminophen is used long-term at high doses.
No acetaminophen or liver monitoring guidance is included in the supplied label excerpts.
No major interactions are reported between Vascepa and antacids such as calcium carbonate (Tums).
No antacid interaction information is provided in the supplied label excerpts.
No major interactions are reported between Vascepa and H2 blockers such as famotidine (Pepcid).
No H2 blocker interaction information is provided in the supplied label excerpts.
No major interactions are reported between Vascepa and PPIs such as omeprazole (Prilosec).
No PPI interaction information is provided in the supplied label excerpts.
Antacids do not affect Vascepa absorption or efficacy.
No absorption/efficacy statements regarding antacids are provided in the supplied label excerpts.
Vascepa is taken with food for better uptake.
The supplied label excerpts provided do not include instructions to take Vascepa with food; only general counseling snippets are included and not dosing instructions related to food.
Antihistamines pose low interaction risk with Vascepa.
No antihistamine interaction information is provided in the supplied label excerpts.
Diphenhydramine may cause additive drowsiness when combined with Vascepa.
The supplied label excerpts do not mention sedation/drowsiness interactions with diphenhydramine.
Non-sedating antihistamines such as loratadine and cetirizine are fine with Vascepa.
No loratadine/cetirizine interaction information is provided in the supplied label excerpts.
Decongestants like pseudoephedrine have no direct interactions with Vascepa.
No pseudoephedrine interaction information is provided in the supplied label excerpts.
OTC cold and sinus products that contain NSAIDs (e.g., Advil Cold & Sinus) carry bleeding risks when used with Vascepa.
No NSAID-specific interaction or OTC product risk guidance is provided in the supplied label excerpts.
Cough medicines with dextromethorphan or guaifenesin are generally safe with Vascepa.
No dextromethorphan/guaifenesin interaction information is provided in the supplied label excerpts.
Multi-symptom OTC products require label checks to avoid hidden aspirin or NSAIDs when taking Vascepa.
The label excerpt does not provide OTC product guidance or mention NSAIDs/aspirin content in OTC combinations.
Avoid additional fish oil or omega-3 supplements with Vascepa.
No supplemental fish oil/omega-3 prohibition or bleeding-risk increase statement is provided in the supplied label excerpts.
Additional fish oil or omega-3 supplements may raise bleeding risk with Vascepa.
The label excerpt says some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time, but it does not specifically state that additional fish oil/omega-3 supplements raise bleeding risk when combined with Vascepa; the provided text is limited to monitoring with anticoagulants/antiplatelets.
Vitamin E at high doses (>400 IU/day) increases bleeding potential when taken with Vascepa.
No vitamin E interaction statement is provided in the supplied label excerpts.
Standard vitamin C and D and multivitamins are safe with Vascepa.
No vitamin C/D/multivitamin interaction safety statements are provided in the supplied label excerpts.
Herbal blood thinners such as ginkgo, garlic, or ginger warrant caution with Vascepa.
No herbal supplement interaction guidance is provided in the supplied label excerpts.
Patients on blood thinners (e.g., warfarin) face higher risks with OTC that affects clotting when taking Vascepa.
The label excerpts only discuss monitoring with concomitant anticoagulants/antiplatelet agents; no OTC “affects clotting” warning is provided.
Patients with bleeding disorders face higher risks with OTC that affects clotting when taking Vascepa.
No bleeding disorder population statement is provided in the supplied label excerpts.
Patients with upcoming surgery face higher risks with OTC that affects clotting when taking Vascepa.
No surgery-related OTC guidance is provided in the supplied label excerpts.
Contradictions
Important Omissions
Provide the label’s quantitative bleeding incidence comparison and seriousness (e.g., 12% vs 10%, serious bleeding 3% vs 2%) and the context that risk is greater with concomitant antithrombotic medications.
Importance:
Moderate
Include the label’s specific drug-interaction management instruction: to monitor patients receiving VASCEPA with concomitant anticoagulants/antiplatelet agents for bleeding.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly highlights increased bleeding risk and increased incidence with concomitant antithrombotic medications and recommends monitoring (supported). However, it also makes many specific interaction and safety claims about NSAIDs, OTC combination products, multiple common drugs/supplements, and dosing thresholds that are not supported by the supplied label excerpts; this could mislead users about which products are or are not safe.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Numerous drug interaction and OTC supplement safety claims are not supported by the provided prescribing-information sections.
Suggested Improvement
Restrict interaction statements to what the label excerpt supports (increased bleeding with concomitant antithrombotic medications such as aspirin/clopidogrel/warfarin and monitoring for bleeding with concomitant anticoagulants/antiplatelet agents) and remove or qualify unsupported specific OTC drug/supplement comparisons, dosing thresholds, and absorption/efficacy assertions not present in the supplied label.